Synonyms: Ontozry® | Xcopri® | YKP-3089 | YKP3089
cenobamate is an approved drug (FDA (2019), EMA (2021))
Compound class:
Synthetic organic
Comment: Cenobamate (YKP-3089) is an oral anti-epilepsy drug. Pharmacological evidence shows that it acts as a positive allosteric modulator (PAM) at GABAA channels [4] and as an inhibitor of the INaP current via voltage-gated sodium channels [3] in isolated rat hippocampal neurons.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Cenobamate inhibits the persistent component of the Na+ current (INaP) with an IC50 value of 53100 nM, in mechanically isolated rat hippocamal neurons in patch-clamp experiments [3]. |
Selectivity at ion channels | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|